Publications by authors named "Martin VoSS"

Claim this Profile
L
Long-term oncologic outcomes of metastatic clear-cell renal cell carcinoma after local therapy alone.
Daniel Barbakoff, Mark T Dawidek, Andrea Knezevic, Marc Ganz, Lina Posada, Martin H Voss

Urol Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanistic insights make cancer cachexia a targetable syndrome.
Ed Reznik, Martin H Voss, A Ari Hakimi

Nat Med· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rubber voice illusion exposed neural correlates of voice perception and vocal adaptation across the continuum of psychosis.
Suong Welp, Andrea Hildelbrandt, David A Magezi, Martin Voss, Laura Kaltwasser

Sci Rep· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line Pembrolizumab Plus Lenvatinib for Advanced Non-clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial.
Martin H Voss, Howard Gurney, Vagif Atduev, Cristina Suarez, Miguel A Climent

Eur Urol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiomic biomarkers associated with immune checkpoint blockade response for advanced renal cell carcinoma.
Stephen W Reese, Daniel Barbakoff, Burcin Agridag Ucpinar, Andrea Knezevic, Kelly Fitzgerald, Martin H Voss

Urol Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physician-led versus questionnaire-based psychosocial screening in adults with high-grade glioma: a cluster-randomized controlled trial (GLIOPT).
Mirjam Renovanz, Melina Hippler, Robert Kuchen, Lorenz Doerner, David Rieger, Martin Voss

J Neurooncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
Rana R McKay, Sumanta Pal, Wanling Xie, David Aggen, Laurence Albiges, Martin Voss

CA Cancer J Clin· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.
Daniel D Shapiro, Edwin Jason Abel, Laurence Albiges, Dena Battle, Stephanie A Berg, Martin H Voss

Urol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of therapeutic targets for renal medullary carcinoma via integrated genomic and transcriptomic profiling.
Pavlos Msaouel, Nizar M Tannir, Funda Meric-Bernstam, Jennifer M King, Martin H Voss

Cell Rep Med· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell Carcinoma.
Mark T Dawidek, Lina Posada Calderon, Parantu K Shah, Rohan Mittal, Burcin Agridag Ucpinar, Martin H Voss

Eur Urol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathologic Response to Immunotherapy Is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma.
Yash S Khandwala, Stephen W Reese, Burcin A Ucpinar, Andrea Knezevic, Lennert Eismann, Martin H Voss

Eur Urol Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ingestion of mast cell granules boosts macrophages and drives atypical programming.
Konstantinos Katsoulis-Dimitriou, Julia Schmidt, Marc Roder, Jan Dudeck, Lars Philipsen, Martin Voss

J Allergy Clin Immunol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma.
Ritesh R Kotecha, Sahil D Doshi, Andrea Knezevic, Rachel Jacobi, Hyung Jun Woo, Martin H Voss

Eur Urol Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated histopathologic modeling of detailed tumor subtypes and actionable biomarkers.
Kevin M Boehm, Madison Darmofal, Arfath Pasha, Andrew Aukerman, Raymond Lim, Martin Voss

bioRxiv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distress screening in patients with high-grade glioma: diagnostic accuracy in relation to a structured clinical interview in a multicenter cluster-randomized controlled trial.
Robert Kuchen, Susanne Singer, Melanie Schranz, Lorenz Doerner, David Rieger, Martin Voss

Support Care Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinoma.
Kathryn E Beckermann, Neil J Shah, Matthew T Campbell, Naomi B Haas, Ariel Nelson, Martin H Voss

Oncologist· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Outcomes and Targeted Genomic Analysis of Renal Cell Carcinoma Brain Metastases Treated with Stereotactic Radiosurgery.
Jennifer Ma, Luke Del Balzo, Henry Walch, Sari Khaleel, Andrea Knezevic, Martin H Voss

Eur Urol Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathologic Response to Immunotherapy is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma.
Yash S Khandwala, Stephen W Reese, Burcin A Ucpinar, Andrea Knezevic, Lennert Eismann, Martin H Voss

medRxiv· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical Trials.
Sahil D Doshi, Andrea Knezevic, Carlene Gonzalez, Patricia Fischer, Robert Goodman, Martin H Voss

Clin Genitourin Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94].
Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, Maria I Carlo, Andrea Knezevic

Eur Urol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency and clinical associations of common mental disorders in adults with high-grade glioma-A multicenter study.
Susanne Singer, Melanie Schranz, Melina Hippler, Robert Kuchen, Carolin Weiß Lucas

Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Kidney Cancer Relapse to Adjuvant Pembrolizumab: Early Insights and Questions for a Newly Emerging Space.
Martin H Voss, Robert J Motzer

Eur Urol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial.
Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, Maria I Carlo, Andrea Knezevic

Eur Urol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214.
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, Thomas Powles, Robert J Motzer, Martin H Voss

J Immunother Cancer· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association between neutrophil-to-eosinophil ratio and efficacy outcomes with avelumab plus axitinib or sunitinib in patients with advanced renal cell carcinoma: post hoc analyses from the JAVELIN Renal 101 trial.
Matthew Tucker, Yu-Wei Chen, Martin H Voss, Bradley A McGregor, Mehmet A Bilen

BMJ Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis